Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Phase IB study of PKC412, an oral FLT3 kinase inhibitor in sequential and simultaneouos combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (patients) with acute myeloid leukemia (AML) under age 61

Phase IB study of PKC412, an oral FLT3 kinase inhibitor in sequential and simultaneouos combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (patients) with acute myeloid leukemia (AML) under age 61. Blood. 2006; 108:51a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.